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Abstract
Evidence is lacking for direct pathogenicity of human anti-proteinase-3 (PR3) antibodies in development of systemic
vasculitis and granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis). Progress in study of these antibodies in
rodents has been hampered by lack of PR3 expression on murine neutrophils, and by different Fc-receptor affinities for IgG
across species. Therefore, we tested whether human anti-PR3 antibodies can induce acute vasculitis in mice with a human
immune system. Chimeric mice were generated by injecting human haematopoietic stem cells into irradiated NOD-scid-
IL2Rc2/2 mice. Matched chimera mice were treated with human IgG from patients with: anti-PR3 positive renal and lung
vasculitis; patients with non-vasculitic renal disease; or healthy controls. Six-days later, 39% of anti-PR3 treated mice had
haematuria, compared with none of controls. There was punctate bleeding on the surface of lungs of anti-PR3 treated
animals, with histological evidence of vasculitis and haemorrhage. Anti-PR3 treated mice had mild pauci-immune
proliferative glomerulonephritis, with infiltration of human and mouse leukocytes. In 3 mice (17%) more severe glomerular
injury was present. There were no glomerular changes in controls. Human IgG from patients with anti-PR3 autoantibodies is
therefore pathogenic. This model of anti-PR3 antibody-mediated vasculitis may be useful in dissecting mechanisms of
microvascular injury.
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Introduction
Systemic vasculitis, comprising microscopic polyangiitis and
granulomatosis with polyangiitis (GPA, Wegener’s granulomato-
sis), is a debilitating and frequently life threatening disease
affecting the microvasculature, in its most severe form manifesting
with acute kidney and lung injury or failure. Its pathogenesis is
only partly understood. Determining the mechanisms by which
systemic vasculitis develops is paramount to developing new
therapies that offer reduced toxicity. A major breakthrough was
made in the 1980’s when several groups discovered autoantibodies
directed at cytoplasmic constituents of neutrophils (Anti-Neutro-
phil Cytoplasmic Antibodies [ANCA]) in patients affected by small
vessel systemic vasculitides [1–5]. These antibodies, which have
specificity for either neutrophil myeloperoxidase (MPO) or
proteinase 3 (PR3), have been shown to activate primed
neutrophils in vitro by binding to cell surface exposed antigens
[6–7] and signalling via Fcc receptors, suggesting a direct
pathogenic role for the circulating antibodies. Further in vitro
studies also lent support to a potential role for monocyte-ANCA
interaction in vasculitis pathogenesis [8].
To study the pathogenicity of these antibodies further,
investigators have attempted both passive transfer and active
immunisation strategies to reproduce systemic vasculitis pathology
in rodents [9–10]. A significant advance was made when Mpo
deficient (Mpo2/2) mice were immunized with murine Mpo to
generate anti-Mpo antibodies [11–14]. These studies confirmed a
pathological role for mouse Mpo antibodies in mice, since passive
transfer of anti-mouse Mpo antibodies to wild-type mice was
sufficient to trigger mild vasculitis. However, the antibodies
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employed in this passive transfer model were raised in Mpo2/2
mice that had never been exposed to the antigen before.
Therefore, they are not autoantibodies and almost certainly have
many different characteristics from antibodies that have arisen as a
consequence of breakdown in tolerance and autoimmunity. A
single report suggesting transfer of anti-MPO positive vasculitis
from mother to neonate, presumably by placental transfer of IgG
[15], provides further support for a pathogenic role for these
antibodies, although it has never been proven in an experimental
setting that human ANCA are sufficient to transfer disease.
Despite many attempts, studies have uniformly failed to develop
a reliable model of anti-PR3 ANCA-associated vasculitis that
proves anti-PR3 antibodies are necessary and sufficient to
cause vasculitis [16–18]. The lack of pathogenicity of anti-PR3
antibodies in experimental systems may relate to three problems
when crossing from humans to mice: 1) human antibodies do not
recognize mouse neutrophil antigens; 2) mouse PR3 is not exposed
at the surface of primed murine neutrophils, unlike on human
neutrophils where it exhibits a bi-modal expression pattern [19]; 3)
Human IgG does not bind to mouse Fcc receptors. To address
these issues we sought to test the function of anti-PR3 antibodies
from patients with systemic vasculitis in mice that have circulating
human neutrophils and monocytes.
Results
Human haematopoietic stem cells reconstitute the
immune system of irradiated immunodeficient mice with
human lymphocytes, monocytes and neutrophils
We first sought to develop and characterise human-mouse
chimeras by infusing mobilized CD34+ human bone marrow stem
cells (HSCs) into sublethally irradiated NOD-scid-IL2Rc2/2 mice.
None of the mice died following irradiation and stem cell injection.
Six weeks after injection of HSCs the extent of chimerism of
circulating leukocytes was assessed, initially by analysis of total
blood leukocytes by flow cytometry. The extent of human
chimerism was assessed by comparing the proportion of
hCD45+ mCD452 leukocytes with total (human and mouse)
CD45+ leukocytes (Table 1). In addition, we assessed the
proportion of mCD452 leukocytes with high side scatter (SSC)
(indicative of granulocytes) by flow cytometry compared with total
high SSC cells to give a sense of the proportion of circulating
granulocytes that were of human origin (Fig. 1A, Table 1) Once
the degree of chimerism was established, mice were divided into
experimental groups, matched for the degree of chimerism. The
fraction of hCD45+/totalCD45+ cells was 24.262.7, 19.163.6,
17.962.4 in recipients of anti-PR3 IgG, disease control IgG and
healthy control IgG respectively (p=NS). To determine more
accurately the proportion of circulating human monocytes and
neutrophils, blood leukocytes were labelled for expression of the
myeloid marker CD11b (antibody recognizes both human and
mouse CD11b) and the neutrophil restricted surface markers
CD15 and CD66b, and analysed by flow cytometry. A significant
population of hCD45+ CD11b+ hCD15+ leukocytes with high
side scatter, or hCD45+ CD11b+ hCD66b+ leukocytes, with high
side scatter was readily detected in all chimeras (Fig. 1B, Table 1),
fulfilling all the criteria of circulating neutrophils. The proportion
of human neutrophils as a fraction of total neutrophils was
17.861.6, 29.162.8, 49.1611.6 in recipients of anti-PR3 IgG,
disease control IgG and healthy control IgG respectively (p=NS).
Next, we studied the proportion of circulating human monocytes
using the markers CD14 and CD16 in addition to CD11b
expression and high forward scatter (FSC) low SSC scatter
characteristics. The human circulating CD11b+ leukocytes
contained a population of CD162 CD14+ and CD16+ CD14low
cells with high FSC, low SSC, fulfilling all the criteria of human
monocytes (Fig. 1D, Table 1). A large proportion of the human
leukocytes expressed the B cell marker CD19 (Fig. 1C) and a
minority were CD11b+ CD192 with scatter characteristics
consistent with human NK cells (Table 1). CD3+ human T
lymphocytes were rare but detectable.
Next, we analysed spleen and bone marrow for chimerism by
flow cytometry. In bone marrow, chimeras had human leukocytes
of myeloid (CD11b+) and lymphoid (CD11b2) lineage (Fig. 1E,
Table 1) and human bone marrow cells included CD14+
leukocytes and CD66b+ leukocytes in keeping with mature human
neutrophils and monocytes residing in bone marrow (Fig. 1E,
Table 1). In spleen, there was significant chimerism. Most human
splenocytes were CD11b2, although there was a small population
of CD16+ CD14low myeloid cells (Fig. 1F, Table 1). Human CD3+
T cells and human CD56+ NK cells were also detected in spleen
(Table 1).
In addition to cell surface markers by flow cytometry, human
multi-lobed neutrophils were readily detected in the chimeric bone
marrow spreads by incubating with anti-human PR3 hIgG or anti-
human MPO hIgG derived from patients with systemic vasculitis
and visualizing the binding with fluorescently conjugated anti-
Table 1. Characterization of the chimeric immune system.
Blood Bone marrow Spleen
% hCD45/total CD45 22.6±2.1 29.6±3.2 12.8±0.9
Monocytes
% total hMono/hCD45 15.1±2.2 7.4±0.7
% CD14high hMono/hCD45 8.761.7
% CD14low hMono/hCD45 6.362.7
% CD11b+CD142/hCD45 12.061.6
% CD11b+CD14+/hCD45 20.862.6
Granulocytes
% total hGranulo/hCD45 15.4±2.1
% hCD66b+neutrophil/hCD45 8.7561.95
% CD16+ neutrophil/hCD45 11.461.9
% hCD15+ neutrophil/hCD45 10.862.1 3.860.4
% hGranulo/total Granulo 33.063.9
Myeloid cells
% CD11b+/hCD45 47.165.2
% CD11b2/hCD45 52.965.2
NK cells
% hNK cells/hCD45 2.2±0.4
%hCD56+ hNK cells/hCD45 3.360.7
T lymphocytes
% hCD3/hCD45 0.34±0.10 1.9±0.3
B lymphocytes
% hCD19+/hCD45 57.1±3.9 65.4±2.5
Blood, bone marrow and splenic digests were analysed by flow cytometry to
define the leukocyte populations (n = 26 mice). Treatment groups were
matched by degree of peripheral blood chimerism prior to IgG injection.
hMono= human monocytes. There was no significant difference in degree of
chimerism or human granulocyte reconstitution between the experimental
groups.
doi:10.1371/journal.pone.0028626.t001
Anti-PR3 ANCA Are Pathogenic
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human IgG (Fig. 1G). Importantly, mouse myeloid cells are not
detected by these antibodies (Fig. 1G).
Preparation and characterization of human anti-PR3
immunoglobulin G
To determine the effect of the protein G-purified anti-PR3
antibodies on neutrophil function, we incubated IgG from healthy
controls or patients with vasculitis with purified, tumour necrosis
factor a (TNFa)-primed, human neutrophils. We determined the
ability of each IgG preparation to stimulate neutrophil degranu-
lation (as assessed by release of MPO from stimulated neutrophils)
and release of superoxide (as assessed by reduction of ferricyto-
chrome C in the presence of superoxide dismutase). On the basis
of these experiments, we selected anti-PR3 IgG preparations that
uniformly stimulated strong superoxide release in all neutrophil
donors, and strong degranulation in two of the three preparations,
Figure 1. Characterization of chimerism in NOD-scid-IL2Rc2/2 mice. (A–D) Flow cytometric analysis of leukocytes from tail bleeds six weeks
after administration of HSCs (n = 26 mice). (A) Plots showing mouse leukocytes labelled with anti-mouse CD45 antibodies. Compared with control
wild-type mouse blood, chimeras have populations of mCD45 negative leukocytes that show SSC characteristics of granulocytes (High), monocytes
(Int) and lymphocytes (low). (B) Chimera blood leukocytes express human CD45 and many of these express CD11b. hCD45+,CD11b+ leukocytes
predominantly express hCD15 and hCD66b compared with hCD45+,CD11b2 leukocytes shown in histograms. (C) A proportion of hCD45+ leukocytes
express CD19. (D) Some hCD45 leukocytes are CD14high and some are CD16+,CD14low. (E) In chimera bone marrow there are CD11b+ leukocytes
which do not express mCD45 and among hCD45+ leukocytes a proportion express CD14 and a proportion express CD66b. (F) In chimera spleen there
are CD11b+ leukocytes which express hCD45 and among hCD45+ leukocytes many express both CD14 and CD16. (G) Bone marrow spreads from wild
type or chimera mice, labelled with anti-hMPO or anti-hPR3 IgG antibodies (red) purified from patients with vasculitis. Note that chimera bone
marrow demonstrates anti-hMPO or anti-hPR3 antibody positive leukocytes with characteristic human neutrophil nuclear morphology. Wild type
mouse bone marrow shows no cells positive for these antigens indicating that the anti-human antibodies do not cross react with mouse neutrophils.
doi:10.1371/journal.pone.0028626.g001
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reasoning that these would have the greatest likelihood of
stimulating disease in mice (Table 2).
Passive transfer of human anti-PR3 ANCA into chimeric
mice causes hematuria and macroscopic lung
haemorrhage
In preliminary studies, lipopolysaccharide (LPS) or TNFa was
administered to wild-type mice to determine their effect on
neutrophil mobilization from bone marrow. Four hours after intra-
peritoneal (IP) injection the proportion of CD45+ circulating
leukocytes that expressed the neutrophil marker Ly6G was
quantified by flow cytometry. LPS enhanced neutrophil recruitment
to the peripheral circulation to a greater extent than TNFa
(38.468.6% versus 18.966.1% of mCD45+ leukocytes respectively,
p,0.05) (Table 3). In order to maximise the number of human
neutrophils in the circulation at the time of antibody injection, and
guided by prior investigations in vitro that indicated ANCA activity is
markedly enhanced following neutrophil or endothelial exposure to
TNFa or LPS, we determined to administer low-dose LPS to all
groups of chimera mice prior to injection of human IgG in order to
mobilize neutrophils into the circulation and increase the likelihood
of triggering vasculitis [10]. To test whether human anti-PR3 IgG is
capable of inducing systemic vasculitis, LPS-treated chimeric mice
were injected next with anti-PR3 IgG or control IgG. Twenty four
hours after administration of anti-PR3 IgG (n=18 mice), disease
control-IgG (n=5 mice), or IgG from healthy controls (n= 3 mice),
seven (39%) of the experimental mice that received anti-PR3 IgG
had developed hematuria, whereas there was no hematuria in
disease or healthy control animals (0%) (p,0.01). There was no
difference in the capacity of anti-PR3 IgG purified from different
patient donors to elicit disease (data not shown). In addition,
experimental mice exhibited albuminuria (53.067.2 mg in anti-PR3
treated versus 36.7617.9 mg in control animals, spot urine
collection) at 24 h. All mice developed some albuminuria, which
may be due to LPS administration. On d6 after injection of human
IgG, mice were all observed to be alive with no signs of distress. The
lungs of 13 of the experimental mice (72%), however, showed areas
of focal pulmonary haemorrhage whereas all lungs of both control
groups (n= 8) appeared normal (p,0.01). Skin, gut and other organs
were macroscopically normal. Therefore, there was evidence of a
systemic vasculitic process following injection of anti-PR3 IgG and
LPS.
Passive transfer of human anti-PR3 ANCA into chimeric
mice causes acute glomerulonephritis
Kidneys and lungs were examined by light microscopy after
staining with hematoxylin & eosin (H&E) and periodic acid-Schiff
(PAS). Fifteen (83%) of the mice treated with anti-PR3 IgG showed
mild disease in kidneys with glomerular hypercellularity. In three
(17%) of the anti-PR3 treated mice, glomeruli showed severe
glomerular injury with proliferation and infiltration in Bowman’s
space of leukocytes, which were primarilymouse in origin (Fig. 2A–C,
F–G & 3). Using standard histological stains the glomerular findings
also comprised: glomerular tuft inflammation, areas of focal pyknosis,
early glomerulosclerosis and periglomerular inflammation with
matrix expansion. There was no significant difference in histological
appearance between mice treated with anti-PR3 IgG preparations
from each of the three patient donors (data not shown). Three (17%)
of the mice treated with anti-PR3 IgG also showed evidence of
moderate interstitial disease with tubule injury, with additional
features of tubule haemorrhage, interstitial matrix expansion; and
interstitial inflammation (Fig. 2D,E,H). The pathological changes
were also evident in kidney cryosections labelled for leukocytes. Most
glomeruli showed recruitment of mouse and human leukocytes to the
glomerulus and periglomerular areas (Fig. 3A–D,G). In addition,
there were leukocytes of both mouse and human origin in the
interstitium of experimental but not control kidneys, and arterioles
had notable perivascular leukocyte recruitment. Human (anti-hMPO
and anti-hPR3+ve) neutrophils were detected in the renal interstitium
of experimental but not control mice (Fig. 3H). Thus, there was
pathological evidence of glomerulonephritis restricted to mice that
had received anti-PR3 ANCA.
Human ANCA associated glomerulonephritis is described as
‘pauci-immune’, due to the lack of co-ordinated deposition of
immune complexes along glomerular basement membrane or in
mesangial or subendothelial spaces. Kidney sections were stained
for the deposition of human IgG and mouse C3. Infiltrating
leukocytes stained positive for human IgG in experimental and
control kidneys, indicating that human IgG is endocytosed by
Table 2. Evidence of bioactivity of human anti-PR3 IgG on primed human neutrophils in vitro.
Stimulus Superoxide release (AUC) Degranulation (OD at 450 nm) Creatinine (mg/dL) Organs involved BVAS
Anti-PR3-1 IgG 12366122 0.3560.06 1.3 K,L,S,N 26
Anti-PR3-2 IgG 1003679 0.5760.1 2.1 K,L 18
Anti-PR3-3 IgG 11806120 0.1360.03 9.1 K,L 20
Disease control IgG 291640 0.126 0.03 1.5 N/A
Healthy control IgG 161616 0.1360.02 N/A
fMLP 13786153 1.0660.10 N/A
IgG samples were incubated with primed human PMNs and superoxide release and degranulation were measured. Each assay was repeated at least 9 times using a
minimum of 4 separate PMN donors. Organs involved: K = kidney, L = lung, S = skin, N =Nasal and sinus. Values represent mean6SEM.
doi:10.1371/journal.pone.0028626.t002
Table 3. Effect of LPS and TNFa on neutrophil recruitment
into the mouse circulation.
LY6G+ cell fraction in peripheral blood leukocytes
Compound Pre-treatment 4 hours 6 days
TNFa 13.663.7% 18.966.1% 11.163.2%
LPS 17.762.5% 38.468.6%* 10.161.5%
WT FVB mice were treated with TNFa (1 mg/kg i.v., n = 3) or LPS (1500 EU/g i.p.,
n = 3) and the degree of PMN mobilisation was quantified by staining peripheral
blood for LY6G.
*p,0.05 compared to pre-treatment value. N = 3/group.
doi:10.1371/journal.pone.0028626.t003
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interstitial cells, but glomeruli showed only weak deposition of IgG and
C3 in all groups (Fig. 3E–G). These results are consistent with anti-PR3
IgG causing a ‘pauci-immune’ disease of the kidney of these mice.
Passive transfer of human anti-PR3 ANCA into chimeric
mice causes lung haemorrhage
Microscopic examination of the lungs from experimental mice
showed patchy areas of haemorrhage with leukocyte recruitment,
particularly of neutrophils to the alveolar walls, and thickening of
alveolar walls. These microscopic features are consistent with
capillaritis (Fig. 4A,B). Strikingly, there were peri-bronchiolar and
peri-alveolar leukocytes in anti-PR3 treated animals, some with
characteristic multi-lobed neutrophil nuclei. In addition, many alveolar
spaces were filled with apoptotic and necrotic cellular debris, partially
engulfed by enlarged alveolar macrophages (Fig. 4C). The number of
leukocytes infiltrating into the lungs was significantly greater in anti-
PR3 treated mice (Fig. 4D). As in the kidney, the majority of recruited
leukocytes to the lung were of mouse origin. By comparison no
leukocytes were recruited to the livers of these mice (data not shown).
Discussion
These studies are the first to report a clear pathogenic role in vivo
for IgG derived from patients with anti-PR3 antibody positive
vasculitis. Anti-PR3 autoantibodies have the capacity to trigger all
the hallmarks of vasculitis in mice with circulating human
neutrophils, and prove therefore that anti-PR3 rich IgG is
important in the pathogenesis of vasculitis. In addition, although
rodent experiments have proven the ability of anti-MPO
antibodies derived from MPO-immunised mice (without evidence
of vasculitis) to induce systemic vasculitis, IgG from actual human
patients with vasculitis has not previously been shown to transfer
the pathological features of vasculitis to rodents. We have shown
that it is possible to transfer disease from humans using antibody
alone, thereby satisfying one of the key criteria for pathogenicity of
these antibodies.
In order to study anti-PR3 antibodies in vivo we were required to
generate mice with a humanized immune system since wild type
mice have no pathogenic response to human anti-PR3 antibodies
(data not shown). In addition, previous attempts to mirror the
approach in murine anti-MPO vasculitis, whereby mice deficient
in PR3 (and elastase) were used to raise antibodies to the target
antigen, have been unsuccessful [16]. These findings therefore
represent a new model to study ANCA associated vasculitis in
rodents, and will be of use to the scientific community. The model
may require further optimization since the extent of kidney disease
was mild compared with lung disease. The extent of disease in
these experiments may reflect the relatively low level of immune
Figure 2. Anti-PR3 antibodies cause kidney disease. (A–C) PAS stained images of glomeruli from chimera mice 6 days after injection with anti-
PR3 (n = 18, A, 4006; C, 6006) or control IgG (n = 8, B, 6006). Note extra-capillary proliferation and peri-glomerular inflammation (arrowhead) (A), and
mesangiolysis (C, arrow) in anti-PR3 treated mice. (D–F) H & E stained sections of kidney from chimera mice treated with anti-PR3 (D, 406) or disease
control (E, 406) IgG. There are regions of tubulointerstitial injury, with red cell cast formation (arrow). (F) Demonstrates intense peri-glomerular
inflammation in an animal treated with anti-PR3 IgG (arrowhead, 4006). By comparison mice treated with disease control IgG showed minimal
glomerular or tubulointerstitial changes. (G) Fractions of glomeruli affected in anti-PR3 (n = 18) and control IgG (n = 8) treated animals (Error bars
depict SEM; ***p= 0.001) (H). Degree of tubulointerstitial disease in mice treated with anti-PR3 antibodies and control antibodies (*P,0.05, median6
IQ 6 max/min values). (Bars = 50 mm).
doi:10.1371/journal.pone.0028626.g002
Anti-PR3 ANCA Are Pathogenic
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system chimerism and in particular the relatively low level of
circulating human granulocytes. It is likely that higher levels of
irradiation prior to stem cell administration, use of neonatal mice
and more potent strategies for recruiting granulocytes from bone
marrow will afford greater levels of myeloid chimerism in future
studies. In previous reports using these NOD-scid-IL2Rc2/2 mice to
generate human chimeras, the extent of peripheral blood myeloid
cell chimerism in NOD-scid-IL2Rc2/2 mice was not well reported
[20]. Here we show unequivocal myeloid chimerism in blood, bone
marrow and spleen. The difference between these studies and earlier
reports may be due to the use of Ficoll density gradients to purify
leukocytes from mouse blood. Ficoll does not separate granulocytes
from erythrocytes and so the extent of granulocytes in the circulation
may have been underestimated previously. In these studies we
exclusively used Cal-lyse which simply lyses all erythrocytes, leaving
all leukocytes including granulocytes for analysis.
It was interesting to note that the majority of recruited
leukocytes in the kidney and lung were of murine origin, although
some infiltrating human leukocytes were observed. This suggests
that the action of the anti-PR3 antibodies on the human
neutrophils (and monocytes) in the chimeric mice led to the
activation of ‘‘danger signals’’ in the recipient mice that led to
recruitment of murine leukocytes in the first instance. The ability
of human leukocytes to marginate, adhere to murine endothelium
and transmigrate into inflamed tissue in these chimeric mice is
questioned. Therefore, it is not surprising that relatively few
human leukocytes were seen infiltrating the tissues. Indeed, the
fact that we observed some, suggests that they do possess the
capability to emigrate from vessels in response to local inflamma-
tory stimuli and chemotactic agents in chimeric mice (presumably
generated by murine cells). We observed human and murine
leukocytes in close proximity in the glomerular lesions. It is thus
likely that some cross talk between the leukocytes of the two species
has occurred, an issue that will require further investigation.
In these proof of principle experiments we observed more severe
lung injury than kidney injury, and no injury or leukocyte
recruitment to other organs. These findings are similar to the
findings in humans where anti-PR3 antibodies have a predilection
for microvascular injury in lung and kidney [29]. Whether this
strain of mice will be more susceptible to lung injury than kidney
injury remains to be determined. Certainly, the studies of Primo
et al suggest that the background strain of the immunodeficient
mouse has an impact on the phenotype, as they observed a
differential effect of transfer of splenocytes derived from murine
PR3-immunised mice into mice of NOD and C57/Bl6 RAG2/2
mice (the latter developed no disease) [21].
All the mice received LPS injections. This was performed to
maximize neutrophil recruitment to the peripheral vasculature
from bone marrow. In addition, LPS triggers endothelial
activation which may be important in the initial trigger for
priming neutrophils for degranulation by anti-PR3 antibodies
[30]. However, the stimulus required to maximally trigger
microvascular disease was not explored. It is not possible to
determine from these studies therefore whether more severe
disease can be triggered by passive transfer of antibodies alone.
The chimera mice generated for these studies did not have CD3+
T lymphocytes of mouse origin and had few CD3+ T lymphocytes
of human origin. Previous studies with this mouse showed
presence of human CD3+ T lymphocytes, although these tended
to develop later than the B cell population and their development
in these mice was highly dependent on continuous administration
of IL7-Fc fusion protein, which we did not administer [22–
23][20]. It is noteworthy that we did not identify any human T
cells in the kidneys of the mice (not shown). Further studies,
therefore, will be required to determine the role of human T
lymphocytes in the pathogenesis of vasculitis in this mouse model,
by generating chimeras and administering IL7-Fc, It is interesting
to note, nevertheless, that vasculitis developed in the presence of
very few T cells. It has been postulated that the reason previous
anti-PR3 models have failed is because they lack effector T cells
[24]; our results suggest that this is not a critical factor, although it
is possible that the phenotype observed would be more severe in
the presence of greater numbers of T cells.
In this report we have demonstrated a model of acute anti-PR3
antibody induced vascular injury that develops over a six-day
period. In addition to this model of acute vasculitis, there is a great
need for the development of models to study the granulomatous
disease seen in GPA. Granulomata are dependent upon a robust
cell mediated T cell response, the pathogenesis of which is almost
certainly separate from the acute vasculitis observed in GPA, and
which develop over a period of weeks or months. Hence, further
refinement of the model to include greater levels of chimerism and
administration of IL7-Fc protein to augment T cell development,
will be required to study this cell mediated response.
To conclude, human anti-hPR3 antibodies from patients with
ANCA associated pulmonary and renal vasculitis have the capacity
to trigger all the features of vasculitis in mice with a humanized
immune system. These findings are consistent with a model in
which primed circulating neutrophils bind anti-PR3 antibodies to
the neutrophil surface at the endothelial interface, with consequent
triggering of neutrophil activation and degranulation, resulting in
capillary injury and a subsequent immune response to the injured
capillary. With further optimisation this model will allow in depth
investigation of anti-PR3 associated vasculitis in vivo.
Materials and Methods
All materials were purchased from Sigma Aldrich and all tissue
culture supplies from Life Sciences unless otherwise stated.
Preparation and selection of human IgG samples
Plasma was collected from the plasma exchange effluent of
patients with active anti-PR3 positive pulmonary and renal
Figure 3. Anti-PR3 antibodies induce infiltration of kidneys with leukocytes of murine and human origin. Kidney sections were
incubated with anti-mCD45 (red) and anti-hCD45 (green) antibodies and images were captured by fluorescence microscopy (T = tubule). Occasional
(,5%) glomeruli of anti-PR3 treated mice displayed intense extracapillary leukocyte infiltration (A) in the shape of crescents (arrows). Most glomeruli
in animals treated with anti-PR3 antibodies (n = 18) had evidence of intraglomerular (B,G) and peri-glomerular (C,G) leukocyte infiltration. These were
comprised mostly of mCD45+ cells, although some hCD45 leukocytes were also present (arrowheads). In addition, there was a significant increase in
peri-vascular leukocyte (mCD45+ and hCD45+) infiltration in anti-PR3 treated mice (D,G [per arteriolar section (art.sec.)]). Sections were also stained
for deposition of IgG [red] (E,G) and C3 [green] (F,G). IgG was detectable within periglomerular cells, but there was minimal deposition within the
glomeruli. Mouse C3 was weakly deposited in glomeruli but was no different between control group (n = 8) and anti-PR3 group (n = 18). Note mouse
C3 can be detected normally binding avidly to tubular basement membranes. (Marker = 10 mm) (*P,0.05, **P,0.01. median6 IQ6max/min values).
(H) Kidney sections from anti-PR3 and control treated animals were incubated with anti-PR3 positive ANCA IgG. In the peritubular capillaries of
chimera mice that received anti-PR3 hIgG occasional leukocytes detected by anti-hPR3 hIgG could be detected. No positively stained human
neutrophils were seen in glomeruli.
doi:10.1371/journal.pone.0028626.g003
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Figure 4. Anti-PR3 antibodies induce capillaritis with leukocytes of mouse and human origin. (A) Photomicrographs of explanted lungs
from mice treated with disease control IgG (n = 8) or from patients with anti-PR3 ANCA (n= 18). Mice treated with anti-PR3 ANCA displayed petechiae
over the surface of the lung. (B) H&E stained low and high power images of lungs from chimera mice injected with anti-PR3 antibodies 6 days
previously. Note hemorrhage, inflammation, thickening of alveolar walls, enlarged, highly vacuolated alveolar macrophages and prominent
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vasculitis undergoing plasmapheresis as part of routine clinical
care. Verbal consent was obtained, and clinical data were collected
in a blinded, coded manner. The Birmingham University (UK)
Ethics Review Board approved this study: UK research ethics
number 5779 (Ethics Statement). All fulfilled Chapel Hill
consensus classification criteria for diagnosis of systemic small
vessel vasculitis [25]. Control IgG was purified from plasma
exchange effluent derived from a patient with membranoproli-
ferative glomerulonephritis (disease control) or pooled plasma from
three healthy donors. Total IgG was separated from plasma using
protein G affinity chromatography as detailed previously [26] and
tested in degranulation and superoxide response assays as detailed
previously [27–28]. In brief, superoxide production was deter-
mined at 37uC using a kinetic microplate assay. 96-well plates
were incubated with 16105 Percoll purified neutrophils/well,
75 mM ferricytochrome C, 300 U/ml superoxide dismutase
(SOD) and stimulus. IgG preparations were added at a
concentration of 200 mg/ml and fMLP was used at 1 mM.
Superoxide production was calculated using a molar extinction
coefficient for ferricytochrome C of 21?16103 M21 cm21.
Superoxide release was tracked for 120 minutes and the area
under the curve was used as the comparator variable. Neutrophil
degranulation was assessed by the release of myeloperoxidase as
described previously [28]. In brief, neutrophils at 2.56106/ml
were primed with TNFa and cytochalasin B and incubated with
200 mg/mL IgG for 15 min. Supernatants were removed and
enzymatic activity was assessed by incubating them with MPO
substrate for 30 minutes and assessing optical density at 405 nm.
We chose the three IgG samples that induced the greatest
superoxide or degranulation response for use in the in vivo
experiments. These were derived during the first plasmapheresis
session of patients with acute pulmonary and renal vasculitis
(Birmingham Vasculitis Activity Score (BVAS) range: 18–26;
mean serum creatinine level 4.2 mg/dL (range 1.3 to 9.1)).
Generation and characterisation of chimeras
Mice with a partially human immune system were generated
using female 8 week old NOD.Cg-Prkdc,scid. Il2rg,
tm1Wjl./SzJ (NOD-scid-IL2Rc2/2) mice (Jackson laboratories),
which lack native T, B and NK cells and the IL2 receptor [20].
Human stem cells were mobilized, purified and characterized from
healthy donors as previously described [30]. Briefly, granulocyte
colony stimulating factor (G-CSF) mobilized apheresis products
obtained from normal healthy adult donors on d5 & 6 after
stimulation were highly enriched for CD34+ cells from the
apheresis product using ISOLEX 300i Magnetic Cell Positive
Selection System (version 2.5, Baxter Healthcare, Deerfield, IL,
USA). We used HSCs from a single donor for all of these studies,
and mice were equally irradiated with a 300cG single dose over
20 mins and then injected by tail vein with 26105 mobilized
human CD34+ hematopoietic stem cells. Mice were maintained in
sterile conditions and monitored as previously described [29]. To
quantify chimerism at six weeks, tail bleeds were performed to
assess peripheral blood leukocytes by flow cytometry. Chimerism
was defined as the proportion of hCD45+ mCD452 peripheral
blood leukocytes compared with total (hCD45+ mCD45+)
leukocytes. All mouse studies were performed according to
protocols overseen and approved by the Animal Resources &
Comparative Medicine at Harvard University (protocol numbers
04464 and 04231) (Ethics Statement).
Flow Cytometry
Purification of blood leukocytes. In order to collect both
granulocytes and PBMCs from mice the Cal-Lyse system
(Invitrogen, CA, USA) was used. Tail bleeds (100 ml) or inferior
vena cava (IVC) bleeds (500 ml) were treated with sodium citrate
(0.38% final concentration). Aliquots were incubated with directly
conjugated primary antibodies 15 min RT, then treated with one
volume of Cal-lyse solution 10 min RT, followed by 10 volumes
of ddH2O and vortexing. After centrifugation (3506g 59) and
washing in PBS, samples were resuspended in fluorescence
activated cell sorting (FACS) buffer [31] and analysed directly
using FACS-Calibur cytomteter. Purification of Bone Mar-
row leukocytes. Whole bone marrow (BM) was purified from
long bones as previously described, subjected to red cell lysis, and
resuspended in FACS buffer. Purification of splenocytes. One
third of the spleen was dissociated by trituration as previously
described [30] and single cells resuspended on ice in FACS buffer.
36105 BM cells or splenocytes were incubated on ice in 100 ml
volume with primary antibodies. After washing and resuspension
in FACS buffer they were fixed with 1% paraformaldehyde (PFA)
solution and analysed using FACSCalibur cytometer. For controls,
we analysed peripheral blood, BM and splenocytes from FVB/N
WT mice. Human leukocytes were purified from a 2 ml blood
sample from a healthy donor. Leukocytes were labelled with the
following antibodies all at 1:200 dilution: anti-hCD45-FITC, or –
PE, hCD3-FITC, anti-hCD56-Al488 anti-hCD16-PE, anti-
CD11b-APC, -PE or -FITC, anti-mCD45-FITC or -PE anti-
mB220-APC (EBioscience), anti-hCD14-Alexa647, anti-hCD19-
APC, anti-hCD15-FITC, anti-hCD66b-FITC (Biolegend), anti-
Ly6C-FITC (BD Pharmingen). In blood, human granulocytes
were defined as hCD45+ CD11b+ cells with high SSC.
Neutrophils were defined as cells with these characteristics and
the expression of hCD15, hCD66b or hCD16. Human monocytes
were defined as hCD45+ CD11b+ cells with low SSC but high
FSC. Subpopulations of monocytes were defined by the level of
expression of CD14. Human NK cells were defined as hCD45+
hCD192, hCD32 cells with low FSC and SSC characteristics or
by expression of hCD56. Human B lymphocytes were defined as
hCD45+ hCD19+ leukocytes with low FSC and SSC character-
istics and human T lymphocytes were defined as hCD45+ hCD3+
cells with low FSC and SSC characteristics. In bone marrow,
mature human neutrophils were defined as hCD45+ CD11b+ cells
with high SSC and expression of hCD15. Mature human
monocytes were defined as hCD45+ CD11b+ cells with low
SSC but high FSC and co-expression of CD14.
Passive transfer of human ANCA to mice
Unlike humans, many mature murine neutrophils and mono-
cytes are held in bone marrow and only released in response to a
stimulus. In preliminary studies the effect of TNFa or LPS (E. coli
026:B6) on mobilization of neutrophils from the BM of FVB/N
recruitment of neutrophils (arrows) within the alveolar walls. These features are consistent with capillaritis. By comparison chimera mice treated with
control IgG showed normal lung architecture. (C) Immunostaining of lung tissue to assess the degree of leukocyte infiltration. Note that in mice that
received anti-PR3 ANCA IgG there was significant recruitment of leukocytes to the peribronchial areas (thin arrows) and also the alveolar areas (fat
arrows). In addition many alveoli in mice treated with anti-PR3 antibodies had apoptotic debris that was partially ingested by alveolar macrophages
(arrowheads) (bar = 50 mm). (D) Blinded assessment of human and mouse leukocyte recruitment to the lungs of treated animals (** P,0.01. median6
IQ 6 max/min values).
doi:10.1371/journal.pone.0028626.g004
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mice into the circulation was studied. Mice were injected with
vehicle, LPS (1500 EU/g/IP) or TNFa (1 mg/kg i.v.). Tail bleeds
were performed pre-injection, at 4 hours and 6 days post injection
(as described above) and mixed leukocytes were labelled with anti-
CD45 and anti-Ly6G antibodies, then separated from RBCs with
Cal-Lyse and analysed by flow cytometry. From these studies it
was determined that LPS best stimulated neutrophil recruitment
into the circulation. Chimera mice were separated into three
matched groups based on the degree of chimerism. Baseline urine
samples were collected. All mice received an IP injection of LPS
(E. coli 026:B6) 1500 EU/g (100 ml). Thirty minutes later mice
they received an IV injection of 4 mg of human IgG (200 ml)
containing anti-PR3 antibodies from 1 of the 3 patients with lung
and kidney vasculitis identified as having a potent effect in vitro on
neutrophil degranulation and superoxide release (n = 18 mice),
human IgG from patients with membranoproliferative glomeru-
lonephritis (n = 5 mice) or human IgG from healthy volunteers
(n = 3 mice). All 3 of the anti-PR3 patients contributed IgG to the
experiment. Urine was collected on d1, d2, d4 and d6 and
analysed for hematuria and proteinuria.
Preparation of tissues for analysis
On d6 after injection, mice were euthanized and 500 ml blood
obtained from the IVC. After flushing blood from the circulation,
spleen and BM were harvested for cell analysis by FACS and in
air-dried cell-spreads on slides [30]. Lungs, heart, trachea were
removed together and inflated with paraformaldehyde-L-lysine-
periodate (PLP) fixative using established methods to ensure
preservation of lung architecture [32]. Kidneys, liver, small
intestine, spleen and skin were collected and fixed with PLP prior
to cryopreservation, or with 10% formalin for 12 h prior to
dehydration with alcohols and paraffin embedding using standard
methods.
Immunostaining and pathological analysis of organs
Kidney and lung 3 mm paraffin sections were stained with PAS
or H&E and analysed for glomerular and interstitial changes.
Glomeruli were scored blindly as normal, mild glomerulonephritis
(.4 cells per mesangial area or .4 cells per capillary loop),
moderate glomerulonephritis (as per ‘‘mild’’ with evidence of
necrosis or tuft disruption) or severe glomerulonephritis (as per
‘‘moderate’’ with extra-capillary or peri-glomerular proliferation).
The interstitium was analysed for interstitial matrix expansion,
inflammation and tubular epithelial cell injury and given a semi-
quantitative score of 0–3 (0 = no injury, 1 = single focus of tubular
injury or peri-tubular inflammation, 2=.one focus of tubular
injury with evidence of peri-tubular inflammation, 3 = extensive
areas of tubular injury with loss of tubular integrity). Arterioles
were examined for the presence of inflammatory cells. All scores
used a 0–3 scale or % positivity as described previously [29,33].
PLP fixed 5 mm cryosections were labelled with anti-mCD45
followed by affinity purified anti-rat IgG-Cy3 antibodies (1:400,
Jackson Immunoresearch), followed by anti-hCD45-FITC anti-
bodies post-fixed with PFA1%, followed by mounting with
Vectashield with DAPI, using methods previously described
[34]. In some experiments, sections were labelled with anti-human
IgG-Cy3 (Jackson Immunoresearch 1:400), or anti-mouse C3-
FITC (Cappell 1:100). Glomeruli were scored blindly for
deposition of IgG or C3 using a scale of 0, not detected; trace;
+; ++; +++. In others, sections and bone marrow cell spreads were
labelled with the anti-human PR3 ANCA IgG used in the transfer
experiment (100 mg/mL) or anti-human MPO ANCA IgG
(100 mg/mL) followed by anti-human IgG-Cy3 (1:400).
Statistical Analysis
Experimental conditions containing two groups were compared
with the Mann Whitney U test or by ANOVA using Stat Plus
(AnalysisSoft, USA) and those with .2 groups were compared
using the Kruskal Wallis test.
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